Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

LAB Research completes US$46 million IPO and secondary offerings

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

LAB Research

On August 3, 2006, LAB Research Inc. completed a $46 million initial public offering and secondary offering of its common shares. The over-allotment option granted by the selling shareholder to the underwriters was exercised in full and closed on September 12, 2006. Pursuant to the option, the underwriters acquired 1.5 million additional common shares for $6 million. LAB Research, which began trading on the Toronto Stock Exchange on August 3, 2006, is a pre-clinical and non-clinical contract research organization that provides contract research services primarily to the pharmaceutical and biotechnology industries. The offering was underwritten by a syndicate of underwriters co-led by Desjardins Securities Inc. and Orion Securities Inc. and including Versant Partners Inc., Westwind Partners Inc., Jennings Capital Inc. and Paradigm Capital Inc. LAB Research was represented by Fasken Martineau with a team that included Michel Boislard, Louis-François Hogue, Frédéric Boucher, Daniel Yelin, Patricia Gagnon, Marie-Josée Vincelli and Alexis Steinman (corporate securities) and Claude Jodoin and Thomas Copeland (tax).

Team

    Subscribe

    Receive email updates from our team

    Subscribe